JP2007501782A - P2x7受容体アンタゴニストとしての2−アダマンチル誘導体 - Google Patents

P2x7受容体アンタゴニストとしての2−アダマンチル誘導体 Download PDF

Info

Publication number
JP2007501782A
JP2007501782A JP2006522527A JP2006522527A JP2007501782A JP 2007501782 A JP2007501782 A JP 2007501782A JP 2006522527 A JP2006522527 A JP 2006522527A JP 2006522527 A JP2006522527 A JP 2006522527A JP 2007501782 A JP2007501782 A JP 2007501782A
Authority
JP
Japan
Prior art keywords
formula
compound
pharmaceutically acceptable
hydroxyl
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006522527A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007501782A5 (cg-RX-API-DMAC7.html
Inventor
デイビッド・クラディングボール
ローナン・フォード
ポール・ウィリス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2007501782A publication Critical patent/JP2007501782A/ja
Publication of JP2007501782A5 publication Critical patent/JP2007501782A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/26—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a saturated carbon skeleton containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
JP2006522527A 2003-08-08 2004-07-28 P2x7受容体アンタゴニストとしての2−アダマンチル誘導体 Pending JP2007501782A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0302192A SE0302192D0 (sv) 2003-08-08 2003-08-08 Novel compounds
PCT/SE2004/001154 WO2005014529A1 (en) 2003-08-08 2004-07-28 2- adamantyl derivatives as p2x7 receptor antagonists.

Publications (2)

Publication Number Publication Date
JP2007501782A true JP2007501782A (ja) 2007-02-01
JP2007501782A5 JP2007501782A5 (cg-RX-API-DMAC7.html) 2007-08-02

Family

ID=27800872

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006522527A Pending JP2007501782A (ja) 2003-08-08 2004-07-28 P2x7受容体アンタゴニストとしての2−アダマンチル誘導体

Country Status (5)

Country Link
US (1) US20070037830A1 (cg-RX-API-DMAC7.html)
EP (1) EP1654217A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007501782A (cg-RX-API-DMAC7.html)
SE (1) SE0302192D0 (cg-RX-API-DMAC7.html)
WO (1) WO2005014529A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012513439A (ja) * 2008-12-23 2012-06-14 エフ.ホフマン−ラ ロシュ アーゲー 自己免疫疾患及び炎症性疾患の処置のための医薬として有用なジヒドロピリドンアミド
JP2016508967A (ja) * 2012-12-12 2016-03-24 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd P2x7受容体アンタゴニストとしてのインドールカルボキサミド誘導体
JP2021520405A (ja) * 2018-03-29 2021-08-19 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック 療法におけるp2rx7モジュレーター

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300480D0 (sv) 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
MXPA05012705A (es) * 2003-05-29 2006-02-08 Astrazeneca Ab Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral.
EP1644042A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
WO2004105797A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
WO2007008157A1 (en) * 2005-07-11 2007-01-18 Astrazeneca Ab New combination 2
US20080207577A1 (en) * 2005-07-11 2008-08-28 Astrazeneca Ab Combination I
CA2670636A1 (en) 2006-11-27 2008-06-05 H. Lundbeck A/S Heteroaryl amide derivatives
EP1935420A1 (en) 2006-12-21 2008-06-25 Merck Sante 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
CN103204852A (zh) 2007-04-10 2013-07-17 H.隆德贝克有限公司 作为p2x7拮抗剂的杂芳基酰胺类似物
CN101711245B (zh) 2007-07-19 2015-03-25 H.隆德贝克有限公司 5元杂环酰胺及相关的化合物
EP2185560A4 (en) * 2007-08-10 2011-10-05 Lundbeck & Co As H HETEROARYLAMIDE ANALOGS
AU2009228649B2 (en) 2008-03-25 2014-05-22 Affectis Pharmaceuticals Ag Novel P2X7R antagonists and their use
DK2243772T3 (da) 2009-04-14 2012-02-13 Affectis Pharmaceuticals Ag Hidtil ukendte P2X7R-antagonister og deres anvendelse
EP2386541A1 (en) 2010-05-14 2011-11-16 Affectis Pharmaceuticals AG Novel methods for the preparation of P2X7R antagonists
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2014097140A1 (en) 2012-12-18 2014-06-26 Actelion Pharmaceuticals Ltd Indole carboxamide derivatives as p2x7 receptor antagonists
KR102035463B1 (ko) * 2018-02-14 2019-11-26 연세대학교 산학협력단 암 줄기세포의 치료용 약학 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001524468A (ja) * 1997-11-21 2001-12-04 エヌピーエス ファーマシューティカルズ インコーポレーテッド 中枢神経系疾患を治療するための代謝調節型グルタミン酸受容体アンタゴニスト
JP2001525391A (ja) * 1997-12-05 2001-12-11 アストラゼネカ ユーケイ リミテッド アダマンタン誘導体
WO2001094338A1 (en) * 2000-06-07 2001-12-13 Astrazeneca Ab Admantane derivatives
JP2002541249A (ja) * 1999-04-09 2002-12-03 アストラゼネカ・アクチエボラーグ アダマンタン誘導体
JP2005528363A (ja) * 2002-03-25 2005-09-22 アストラゼネカ・アクチエボラーグ 新規アダマンタン誘導体

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471491A (en) * 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
US4349552A (en) * 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
US5399564A (en) * 1991-09-03 1995-03-21 Dowelanco N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides
NZ332341A (en) * 1996-05-20 2000-05-26 Darwin Discovery Ltd Quinoline carboxamides as TNF inhibitors and as PDE-IV inhibitors
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9904505D0 (sv) * 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) * 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
CA2452606C (en) * 2001-07-02 2011-09-13 Akzo Nobel N.V. Tetrahydroquinoline derivatives
WO2003042190A1 (en) * 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
SE0103836D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
US6908939B2 (en) * 2001-12-21 2005-06-21 Galderma Research & Development S.N.C. Biaromatic ligand activators of PPARγ receptors
SE0300445D0 (sv) * 2003-02-18 2003-02-18 Astrazeneca Ab New combination
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
WO2004105797A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
EP1644042A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
MXPA05012705A (es) * 2003-05-29 2006-02-08 Astrazeneca Ab Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral.
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001524468A (ja) * 1997-11-21 2001-12-04 エヌピーエス ファーマシューティカルズ インコーポレーテッド 中枢神経系疾患を治療するための代謝調節型グルタミン酸受容体アンタゴニスト
JP2001525391A (ja) * 1997-12-05 2001-12-11 アストラゼネカ ユーケイ リミテッド アダマンタン誘導体
JP2002541249A (ja) * 1999-04-09 2002-12-03 アストラゼネカ・アクチエボラーグ アダマンタン誘導体
WO2001094338A1 (en) * 2000-06-07 2001-12-13 Astrazeneca Ab Admantane derivatives
JP2005528363A (ja) * 2002-03-25 2005-09-22 アストラゼネカ・アクチエボラーグ 新規アダマンタン誘導体

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012513439A (ja) * 2008-12-23 2012-06-14 エフ.ホフマン−ラ ロシュ アーゲー 自己免疫疾患及び炎症性疾患の処置のための医薬として有用なジヒドロピリドンアミド
JP2016508967A (ja) * 2012-12-12 2016-03-24 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd P2x7受容体アンタゴニストとしてのインドールカルボキサミド誘導体
JP2021520405A (ja) * 2018-03-29 2021-08-19 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック 療法におけるp2rx7モジュレーター
US11919854B2 (en) 2018-03-29 2024-03-05 Centre National De La Recherche Scientifique P2RX7 modulators in therapy

Also Published As

Publication number Publication date
US20070037830A1 (en) 2007-02-15
EP1654217A1 (en) 2006-05-10
SE0302192D0 (sv) 2003-08-08
WO2005014529A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
US20070037830A1 (en) 2-Adamantyl derivatives as p2X7 receptor antagonists.
US7227038B2 (en) Adamantane derivatives, processes for their preparation and pharmaceutical composition containing them
JP4001542B2 (ja) N−アルキル−アダマンチルトリアジニルベンズアミド誘導体
JP5270542B2 (ja) Crth2アンタゴニスト活性を有する化合物
JP4560411B2 (ja) 炎症性疾患の治療のためのp2x7阻害剤としての3−(3,5−ジオキソ−4,5−ジヒドロ−3h−(1,2,4)トリアジン−2−イル)−ベンズアミド誘導体
JP4365218B2 (ja) P2x7受容体アンタゴニストとしてのベンズアミドおよびヘテロアリールアミド
JP4731468B2 (ja) P2x7受容体のベンズアミド阻害剤
US20080058293A1 (en) Quinoline Derivates and Their Use in Therapy
US20100022613A1 (en) Compounds Having CRTH2 Antagonist Activity
JP2006513205A (ja) P2x7受容体のベンズアミド阻害剤
JP2007501270A (ja) P2X7受容体アンタゴニストおよび腫瘍壊死因子αを含む医薬組成物
ES2274295T3 (es) Nuevos derivados de piperidina como moduladores del receptor ccr5 de la quimioquina.
JP2009520781A (ja) 炎症性疾患の処置のためのc−cケモカイン(ccr2bおよびccr5)のアンタゴニストとして有用なピペラジン化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070605

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100420